Business ❯ Pharmaceutical Industry ❯ Drug Development

Clinical Trials

Eli Lilly Market Impact Market Analysis Market Competition Market Access Novo Nordisk FDA Approval FDA Approvals Product Recall Mounjaro Mounjaro Impact Pfizer's weight-loss pill candidates FDA Regulations Vertex Pharmaceuticals Zepbound Market Potential Regulatory Compliance Innovative Treatments AIO-001 Hi1a Drug Trial Results Aduhelm Study Obesity Treatment Liver Disease Treatment Bayer AG UGN-102 FDA Approval Process HIV Prevention Drugs Bioavailability Merck & Co. Inc. Market Regulation Immunotherapy Market Trends Market Approval Eli Lilly and Co. Real-World Evidence Lilly Regulatory Approval Post-Marketing Activities Sarepta Therapeutics Phase II Trials Competition Among Companies Psychedelic Companies Cytokinetics AstraZeneca Gilead Sciences Market Challenges

Valneva Pulls U.S. Filings for Chikungunya Vaccine as FDA Halts Trials Over Safety Review

The decision follows FDA scrutiny of a foreign serious adverse event potentially linked to Ixchiq, with causality still undetermined.

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

FDA Outlines 'Plausible-Mechanism' Pathway to Speed Bespoke Therapies

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

FDA Clears Monthly Uzedy Injection for Maintenance Treatment of Bipolar I Disorder

FDA Opens Door to Reconsider Capricor’s Duchenne Cell Therapy Based on HOPE-3 Data

Bristol Myers’ Iberdomide Combo Hits MRD Goal in Phase 3 Myeloma Study

FDA Approves Keytruda QLEX, a Rapid Subcutaneous Option for Most Adult Solid Tumor Uses

FDA Approves First New Fibromyalgia Treatment in 15 Years